Document is current
Any future updates will be listed below
-
Authors
Cornish, E. E. https://orcid.org/0000-0003-3898-8811
Wickremasinghe, S.
Mehta, H.
Lim, L. https://orcid.org/0000-0003-2491-685X
Sandhu, S. S.
Nguyen, V.
Gillies, M. C.
Fraser-Bell, S. https://orcid.org/0000-0001-5646-9359
-
Funding
Funding for this research was provided by:
Consultant - Allergan, Bayer, Novartis, Roche
Consultant - Bayer, Novartis, AbbVie, Speaker fees - Bayer, AbbVie
Allergan
Personal fees - Bayer, Consultant - Allergan, Novartis, Bayer Expert testimony - Bayer
- License Information
-
More Information
Article History
Received: 8 August 2022
Revised: 21 March 2023
Accepted: 5 April 2023
First Online: 17 April 2023
Competing interests
: EEC: no financial disclosures; SW: no financial disclosures; HM: Consultant—Allergan, Bayer, Novartis, Roche; LLL: Consultant—Bayer, Novartis, AbbVie, Allergan; Speaker fees—Bayer, AbbVie; SSS: no financial disclosures; VN: no financial disclosures; MCG: Grant—Allergan; Personal fees—Bayer; Consultant—Allergan, Novartis, Bayer; Expert testimony—Bayer; SFB: Consultant—Allergan, Bayer, Novartis, Roche.
